The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
 
Andrew Kuykendall
Honoraria - Abbvie/Genentech; Blueprint Medicines; BMS; GlaxoSmithKline; Incyte; MorphoSys; Opna Bio; Pharmaessentia; SOBI
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Karyopharm Therapeutics; Keros Therapeutics; MorphoSys; Protagonist Therapeutics
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Geron (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Pharmaessentia; Protagonist Therapeutics
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Kristen Pettit
Consulting or Advisory Role - AbbVie; Merck
Travel, Accommodations, Expenses - Merck
 
Joseph Shatzel
Consulting or Advisory Role - Aronora
 
Alessandro Lucchesi
Consulting or Advisory Role - Amgen; Grifols; MorphoSys; Novartis; Protagonist Therapeutics; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Grifols; Incyte; Novartis; Pfizer; Sanofi; SOBI
 
Valentin García-Gutierrez
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ASD Healthcare; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis; Pfizer
 
Jirí Mayer
Research Funding - BeiGene; Protagonist Therapeutics; Roche
 
Abdulraheem Yacoub
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Apellis Pharmaceuticals; Bristol-Myers Squibb; CTI; Gilead Sciences; Incyte; Notable Labs; Novartis; Pfizer; PharmaEssentia; SERVIER
 
Harinder Gill
Honoraria - Astellas Pharma; BMS; GlaxoSmithKline; MSD; Novartis; Otsuka; Pharmaessentia
Consulting or Advisory Role - GlaxoSmithKline; PharmaEssentia
Research Funding - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pharmaessentia
Patents, Royalties, Other Intellectual Property - COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS (International publication number: WO 2023/011624 Al); The University of Hong Kong currently holds two United States (US) patents (7,521,071 B2 and 8,906,422 B2), one Japanese patent (4786341) and one European patent (EP 1562616 B1) for the use of oral arsenic trioxide in the treatment of leukemias and lympho (Inst)
Travel, Accommodations, Expenses - BMS; Jacobson Pharma Corporation (Hong Kong); MSD; Novartis; Otsuka; Pfizer; Pharmaessentia
 
Antonin Hlusi
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Novo Nordisk; Octapharm; SOBI
 
Daniel Sasca
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences
 
Joseph Scandura
Consulting or Advisory Role - Abbvie; Calico; Incyte; Karyopharm Therapeutics; Morphic Therapeutic; Novartis/Constellation; PharmaEssentia; SDP Oncology
Research Funding - Abbvie (Inst); SDP Oncology (Inst)
 
Marina Kremyanskaya
Consulting or Advisory Role - Agios; Disc Medicine; Incyte; Kura Oncology; Protagonist Therapeutics; Silence Therapeutics
Research Funding - MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst); Silence Therapeutics (Inst); Sumitomo Chemical (Inst)
 
Phil Dinh
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Sarita Khanna
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
Travel, Accommodations, Expenses - Protagonist Therapeutics
 
Suneel Gupta
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Arturo Molina
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Aniket Bankar
Consulting or Advisory Role - Jazz Pharmaceuticals; Protagonist Therapeutics
 
on behalf of the VERIFY Investigators
No Relationships to Disclose